… tool to determine which patients derived particular mortality benefit from SGLT2i. The high
… In contrast, our analyses did not show a mortality benefit with dapagliflozin in patients with …

… mortality. To better understand the effects of dapagliflozin on cause-specific mortality across
… with symptomatic HF to treatment with dapagliflozin or placebo but enrolled adjacent …

… dapagliflozin have been shown to reduce rehospitalization and cardiac mortality in patients
with heart failure (… all-cause mortality of ARNI and dapagliflozin combination therapy against …

… Failure trial (DAPA-HF) is an international, multicentre, … with chronic heart failure, evaluating
the effect of dapagliflozin 10 … outcome of a worsening heart failure event (hospitalization or …

… Dapagliflozin was also as effective at reducing mortality in patients with a history of HF as
in those with no history of HF. Because patients with HF had a much higher risk of premature …

… of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in
patients with heart … Dapagliflozin in patients with heart failure and reduced ejection fraction.  …

… Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive
either dapagliflozin (at … The primary outcome was a composite of worsening heart failure (…

… co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart …
death or worsening heart failure when dapagliflozin was initiated in patients with heart failure with …

… dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with
heart failure … death remains the principal cause of mortality in ambulatory patients with HFrEF, …

… heart failure, b all-cause mortality, c cardiovascular mortality, … heart failure, all-cause mortality,
cardiovascular mortality, and major adverse cardiovascular events between dapagliflozin …